Amyris CEO on the post-bankruptcy re-boot: ‘We’re a drastically different company’
Two years after emerging from bankruptcy, biomanufacturing specialist Amyris is not yet profitable, but is a “drasticall…
Oculis drops plans for diabetic macular edema drug after Phase III miss
The Zug-based company said the DIAMOND-1 and DIAMOND-2 trials did not show a statistically meaningful improvement in best corrected visual acuity after 52 weeks of treatment compared with vehicle. The result is particularly damaging because visual acuity was the primary endpoint of the programme and the basis for a potential regulatory filing.
Neuropixels Opto Integrates Electrophysiology and Optogenetics to Probe Neuronal Function
High-resolution extracellular electrophysiology is typically used to record from neurons in order to understand brain function. Combining electrophysiology with optogenetics allows researchers to test the causal role of specific neurons by activating or inactivating those populations while recording the effects of neural activity.
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn
Under the agreement, Servier will pay US$1.55bn upfront and up to US$1.1bn in regulatory and commercial milestones. The transaction, unanimously approved by the boards of both companies, is expected to close in the third quarter of 2026.
RNA生物农药产业化窗口正在打开——这是中国农化企业布局新赛道的入场时机吗?
全球农药市场正在发生一场深层转变:法规收紧、传统活性成分加速退出、绿色植保需求持续升温——化学农药企业面临的压力有目共睹。与此同时,RNA生物农药这一被誉为继化学农药、微生物农药之后最具潜力的新一代植保技术,正在全球范围内从"实验室概念"加速走向真实产品。中国创新力量深度参与其中,并正在带着可落地的产业化成果走向行业视野。
Macrocyclic Peptide Drugs Unlocked, Membrane Permeability Screened at Scale
Macrocyclic peptides are a promising drug modality that combine the oral convenience of small molecules with the high specificity of large biologics. Yet, they struggle with cell membrane permeability, limiting their ability to target disease interactions within cells.
T-CURX buys Pantherna as the race for in vivo CAR-T gathers pace
With this merger, there is no need to chase down the financial volume with investigative zeal and try to determine what order of magnitude the deal might fall into. That is not what matters here. At first glance, the acquisition may look like a relatively small merger between two smaller German biotech companies, and the casual reader may simply move on. Behind it, however, lies a strategic trend that is currently preoccupying the cell therapy industry: the development of so-called in vivo CAR-T therapies.
美国佛蒙特州率先立法禁用百草枯:暴露者帕金森病风险高出250%
世界农化网中文网报道:佛蒙特州近日正式签署法案,成为全美第一个禁用除草剂百草枯的州。该决定基于大规模流行病学研究结果:接触百草枯的人群患帕金森病的风险约高出250%。这一风险不仅限于直接施用者,由于药剂漂移的可能,在农田附近生活、工作或上学的居民同样面临暴露威胁。
中农联合创制杀菌剂氟喹菌酯对大白菜软腐病田间防效优异
世界农化网中文网报道:5月27日,国家农业科技专项″防治稻蔬细菌性病害药剂的创制与产业化关键技术″课题组在江苏省东台市弶港镇召开了新型药剂氟喹菌酯防治大白菜软腐病的田间防效观摩会。
新一批74个转基因玉米/大豆初审公示,涉及8种转化体,大北农独占62%
世界农化网中文网报道:2026年5月29日,农业农村部发布公告公示第五届国家农作物品种审定委员会第十二次审定会议初审通过的转基因玉米、大豆品种相关信息,73个转基因玉米和1个转基因大豆品种拟通过国审初审。
